LA JOLLA, Calif., Feb. 7, 2008 (PRIME NEWSWIRE) -- Duska Therapeutics, Inc. (OTCBB:DSKA), a biopharmaceutical company developing diagnostic and therapeutic products based on adenosine 5'-triphosphate (ATP) and P2 receptor-related technologies, announced today that the results of a study sponsored by the company and published in the journal of Reproductive Sciences shows the motility of human sperm is enhanced by extracellular ATP. (Scott E. Edwards, et al., “Effects of Extracellular Adenosine 5'-Triphosphate on Human Sperm Motility,” 2007; 14: 655-666).
